Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jenoptik (Germany) modifies flotation plan

This article was originally published in Clinica

Executive Summary

Plans to float Jenoptik (Germany) on the stock exchange in 1998 are to continue but will start with profitable subsidiaries rather than the holding company (see Clinica No 669/70, p 14). Jenoptik's chairman, Lothar Spath, says that floating the entire company together with its 40 subsidiaries would not be an attractive proposal for the stock exchange, reports Handelsblatt. In 1995 Jenoptik expects a turnover of DM 1,000 million ($700 million) and a balanced profit and loss account. Jenoptik Laser, Optik, Systeme is one of the poorly performing subsidiaries that is unlikely to be included in the flotation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT094176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel